Introduction {#Sec1}
============

Pancreatic cancer is known to have a high frequency of postoperative recurrences and a poor prognosis. Pancreatic cancer is now the fifth leading cause of cancer-related deaths in Japan \[[@CR1]\], and most patients develop a recurrence of the same cancer within 1 or 2 years after tumor removal \[[@CR2]\]. The most frequent recurrence patterns for pancreatic cancer after resection are local recurrence, hepatic metastasis, and peritoneal dissemination \[[@CR3]--[@CR6]\]. The high frequency of reported recurrences has been attributed to malignant cells remaining on resected margins in up to 50 % of cases even after macroscopically curative resection \[[@CR7]\]. This R1-like situation could explain the high local recurrence rate \[[@CR7]\]. Another reason is the presence of systemic occult disease at the time of operation in most of the patients, which could lead to distant metastasis in the liver (50 % of resected patients) or peritoneum (25 %) \[[@CR5], [@CR7]--[@CR9]\].

Remnant pancreatic cancer sometimes appears in survivors after curative resection for invasive ductal adenocarcinoma of the pancreas (PDAC). However, there are few reports on the development of pancreatic cancer in the remnant pancreas after pancreatectomy \[[@CR1]\], \[[@CR10]\]. Consequently, the clinical characteristics of remnant pancreatic cancer after curative resection for PDAC are not well known. The aim of this study was to evaluate clinicopathological findings regarding remnant pancreatic cancer in PDAC survivors.

Materials and methods {#Sec2}
=====================

Between 1980 and 2011 at the Department of Gastroenterological Surgery of Tokyo Women's Medical University, 826 patients who had curative resections for PDAC were studied retrospectively. The remnant pancreatic cancer was detected by means of the serum levels of carcinoembryonic antigen and CA19-9 as well as computed tomography (CT), abdominal ultrasonography, and magnetic resonance imaging (MRI).

The patients were followed up in the outpatient clinic of our hospital or a related hospital and clinic every 3--6 months, and most of the follow-up data collected from these clinical hospital files were studied. (They were evaluated by examination every 3--4 months in the outpatient clinic of our hospital and every 3--6 months in the related hospital and clinic.)

A remnant pancreatic cancer was defined by the following criteria: (1) pathologically negative surgical margins at the first surgery (R0 operation) without M1 but with extra regional lymph nodes according to the UICC. (2) No recurrent tumor detected by CT or MRI examination within 1 year after the first operation. (3) The tumor appeared to develop and exist in the remnant pancreas. Twenty-three patients (2.8 %) fulfilling these criteria were ultimately employed for this retrospective study (Table [1](#Tab1){ref-type="table"}).Table 1Characteristics of primary pancreatic cancerPrimary operationNoAgeGender (M/F)LocationOperationDifferentiationTumor size(mm)UICCStagePancreatic duct marginPreoperative CA19-9 levels(U/ml)Postoperative adjuvant chemotherapy167MHeadPDModerately25T3N1M0IIB(−)Not described(−)266FBodyDPModerately30T2N0M0IB(−)56(−)354MBodyDPModerately17T3N0M0IIA(−)Not described(−)453MHeadPPPD+PVWell15T3N0M0IIA(−)1(−)563MHeadPPPDModerately13T1N0M0IA(−)Not described(−)672MHeadPD+PVModerately30T3N0M0IIAdysplasiaNot described(−)757MHeadPDModerately15T3N1M0IIB(−)19(−)860MBodyDPWell33T3N0M0IIA(−)179GEM956MHeadPPPDModerately45T3N1M0IIB(+)1910S-11059FHeadPPPD+PVmoderately37T3N1M1IV(−)420GEM1155MHeadPPPD+PVModerately45T3N0M0IIA(+)784GEM1258FBodyDPModerately30T3N0M0IIA(+)Not described(−)1382MBodyDP+PVModerately20T3N0M0IIAPanIN-1B8(−)1469MBodyDPModerately15T3N0M0IIA(−)113(−)1559FHeadDPPHRPoorly15T3N0M0IIA(−)64(−)1655FBodyDP+AceModerately80T3N1M1IV(−)362immunotherapy1762MHeadPPPD+PVModerately30T3N1M0IIB(−)138GEM1865FBodyDPModerately15T1N0M0IA(−)15(−)1970FBodyDorsal pancreas resection+DPModerately13T2N0M0IB(−)14GEM2057MHeadPPPD+PVModerately15T3N1M0IIB(−)19GEM2148MBodyDPPapillary25T3N0M0IIA(−)24GEM+immunotherpy2282FBodyDPModerately15T3N1M0IIB(−)9GEM+immunotherpy2363FHeadPPPDWell20T3N1M0IIB(−)84S-1*PD* pancreaticoduodenectomy, *DP* distal pancreatectomy, *PPPD* pylorus preserving PD, *PV* portal vein resection and reconstruction, *DPPHR* duodenum preserving pancreas head resection, *y* year, *m* month, *IOR* intraoperative radiation, *BSC* best supportive care, *SSPPD* subtotal stomach preserving pancreaticoduodenectomy, *IPMC* intraductal papillary mucinous carcinoma *GEM* gemcitabine

All of these 23 cases were pathologically confirmed by histological information to be PDAC with R0 treatment at the first operation. Clinicopathological features including sex, age, primary and secondary tumor characteristics, and long-term survival data were collected from hospital records. These factors related to the primary operation including sex, age, location, operation, degree of differentiation, tumor size, N of UICC (lymph node state), pancreatic duct margin, preoperative CA19-9 levels, perineural invasion, and postoperative adjuvant chemotherapy were analyzed using both univariate and multivariate analyses.

Statistical analysis {#Sec3}
--------------------

The survival times of unresected and resected patients were estimated using the Kaplan--Meier method and compared using the log-rank test. A univariate and multivariate Cox proportional hazards model was used to evaluate which factors demonstrated an independent effect on disease-free intervals (DFIs). *P* values less than 0.05 were considered statistically significant. Analysis was performed using SPSS Statistics 22.0 (IBM Corp., Chicago, IL).

Results {#Sec4}
=======

At the first surgery, the tumor was located in the pancreatic head in 12 patients and in the pancreatic body in 11 patients. Pylorus-preserving pancreatoduodenectomy (PPPD) was performed in 8 patients, pancreatoduodenectomy (PD) in 3 patients, duodenum-preserving pancreatic head resection (DPPHR) in 1 patient, and distal pancreatectomy (DP) in 11 patients (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). A well-differentiated tubular adenocarcinoma was detected in 3 patients, a moderately differentiated tubular adenocarcinoma in 18 patients, a papillary adenocarcinoma in 1 patient, and a poorly differentiated adenocarcinoma in 1 patient. These patients were classified into stages according to UICC classification as follows: 2 in IA, 2 in IB, 10 in IIA, 7 in IIB, and 2 in IV. All patients underwent curative resection. The median and mean DFIs for these patients were 53.6 and 74.2 months (range, 15--240), respectively. Regarding treatment procedures, 12 patients underwent total excision of the remnant pancreas, 6 received chemotherapy, and 5 received the best supportive care (BSC). The six patients treated with chemotherapy consisted of four who received chemotherapy after refusing surgery despite resectable PDAC and two with unresectable PDAC due to locally advanced tumors. The five BSC patients consisted of three with unresectable PDAC (2 with locally advanced tumor and 1 with liver metastasis) and two with resectable PDAC who refused surgery.Table 2Characteristics of remnant pancreatic cancerRemnant operationNoDFITreatmentDifferentiationUICCStagePrognosis(after 2nd operation)Recurrence form120 yearsBSC(resection impossible)(−)Death(6 m)Peritoneum211 year 11 monthRemnant pancreas resection+PVModeratelyT3N1M0IIBDeath(11 month)Peritoneum39 year 5 monthChemotherapy(resection possible)(−)Death(3 year)Liver, peritoneum410 year 1 monthChemotherapy(resection possible)(−)Death(1 year 4 month)Liver, peritoneum510 year 2 monthBSC(resection impossible)(−)Death(6 month)Liver, peritoneum69 year 9 monthBSC(resection impossible)(−)Death(2 month)Liver, peritoneum, lung79 year 2 monthRemnant pancreas resection+remnant stomach resection+IORModeratelyT3N1M0IIBDeath(4 month)Pleura85 year 8 monthRemnant pancreas resectionWellT1N0M0IAAlive(7 year)(−)96 year 3 monthRemnant pancreas resectionModeratelyT3N0M0IIAAlive(1 year 3 month)(−)104 year 5 monthChemotherapy(resection possible)(−)Death(1 year 6 month)Liver, peritoneum112 year 5 monthChemotherapy(resection possible)(−)Death(9 month)Liver, peritoneum122 year 5 monthRemnant pancreas resectionModeratelyT3N0M0IIADeath(2 year 1 month)Liver133 year5 monthBSC(resection possible)(−)Death(10 month)Liver, peritoneum143 year 3 monthRemnant pancreas resection+PVWellT3N1M0IIBDeath(2 year 6 month)Liver, lung152 year 9 monthRemnant pancreas resectionPoorlyT3N0M0IIAAlive(7 year 6 month)(−)162 year 6 monthRemnant pancreas resection+remnant stomach resectionIPMCTisN0M00Alive(8 month)(−)171year 3monthDPModeratelyT3N1M0IIBAlive(3 year)Peritoneum182 year 7 monthDPPHRIPMCTisN0M00Alive(3 year 8 month)(−)192year 9 monthChemoradiotherapy(resection impossible)(−)Death(12 month)Peritoneum202 year 8 monthRemnant pancreas resectionModeratelyT3N1M0IIBAlive(6 month)(−)2113 year 1 monthChemoradiotherapy(resection impossible)(−)Dead(4 year 5 month)Peritoneum221 year 6 monthBSC(resection possible)(−)Dead(2 year 2 month)Peritoneum235 year 2 monthRemnant pancreas resectionModeratelyT3N1M0IIBAlive(1 month)(−)*DFI* disease free interval *PD* pancreaticoduodenectomy, *DP* distal pancreatectomy, *PPPD* pylorus preserving PD, *PV* portal vein resection and reconstruction, *DPPHR* duodenum preserving pancreas head resection, *y* year, *m* month, *IOR* intraoperative radiation, *BSC* best supportive care, *SSPPD* subtotal stomach preserving pancreaticoduodenectomy, *IPMC* intraductal papillary mucinous carcinoma *IOR* intraoperative radiation therapy

The pathological findings of the remnant pancreas in the 12 resected cases were PDAC in 10 patients and intraductal papillary mucinous carcinoma with an associated invasive carcinoma in 2 patients. The 12 patients were found to be in the following stages (UICC classification): 2 in 0, 1 in IA, 3 in IIA, and 6 in IIB. The same histopathological features in specimens from the first and second operations were recognized in 8 of the 12 (67 %) cases. The mortality and morbidity rates of resected patients were 0 and 41.6 %, respectively. Complications were observed in five patients: 2 with delayed gastric emptying, 2 with intra-abdominal abscess, and 1 with sepsis. The average length of hospital stay was 34 days (13--70). No unresected patients had survived, and eight patients who underwent total excision of the remnant pancreas survived. The 5-year survival rate for all the 826 studied resected pancreatic cancer patients was 21.3 %. The mean and median survival times after the second operation were 23.7 (range, 1--90) and 31.6 months, respectively. The 1-year and 3-year survival rates and the median survival time were 45.5, 9.1 %, and 12 months for unresected patients, respectively, contrasting with 79.6, 53 %, and not obtained for resected patients, respectively (*P* = 0.0049 by log-rank test) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Kaplan-Meier curve for overall survival between resected and unresected patients for the remnant pancreatic cancer

Recurrences were observed in 16 patients (13 with peritoneal dissemination \[56.5 %\], 9 with liver metastasis \[39.1 %\], 2 with lung metastasis \[8.7 %\], and 1 with pleural metastasis \[4.3 %\]). A univariate analysis for DFI showed no significant difference by any of clinicopathological features. None of the lymph node state, degree of differentiation, and perineural invasion could predict survival. Therefore, multivariate analysis for DFI could not have been investigated.

Discussion {#Sec5}
==========

The 5-year survival rate reported after surgical resection of PDAC is approximately 20 % \[[@CR11]\]. Most patients develop recurrence within 1 or 2 years after tumor removal \[[@CR3], [@CR12], [@CR13]\]. The surgical mortality rate associated with pancreatectomy has decreased to less than 5 % despite high morbidity rates and recent improvements in operative technique and perioperative management that have resulted in an increase in the number of long-term survivors after pancreatectomy \[[@CR14]--[@CR20]\]. Thus, there have been some recent reports regarding cases of remnant pancreatic cancer after pancreatectomy \[[@CR21]--[@CR24]\]. We evaluated clinicopathological findings of the remnant pancreatic cancer in survivors of PDAC.

It is difficult to define whether a pancreatic carcinoma developing in the remnant pancreas after a pancreatectomy for PDA is a local recurrence or a newly developed primary cancer \[[@CR2]\]. The remnant pancreatic cancer was defined in this study according to those criteria mentioned earlier. In the literature, the time interval from primary PDA to remnant pancreatic cancer ranges from 12 to 89 months (mean 37.6 months), using our definition (Table [3](#Tab3){ref-type="table"}) \[[@CR1], [@CR2], [@CR21]--[@CR30]\]. On the other hand, the time interval in our studied cases ranged from 15 to 240 months (mean 74.2 months) (Table [2](#Tab2){ref-type="table"}), which is much longer than the previous reports. This result suggests that long-term follow-up after surgery for PDAC may be needed even beyond 5 years to monitor for remnant pancreatic cancer. In Japan, postoperative follow-up of patients with resected pancreatic cancer by means of CT or MRI examination every 3--6 months is generally warranted and covered by insurance. Because most patients with resected pancreatic cancer are likely to develop recurrence soon after resection, an intensive follow-up schedule is considered necessary to find recurrence in a remnant pancreas. Whether such intensive follow-up could be performed for the long term may be debatable when considering cost-effectiveness. The results of this study indicated that a newly developed cancer in the remnant pancreas could be detected by performing CT or MRI examination every 6--12 months for patients having survived for 5 years. Such long-term survivors could be few, but it is important to implement intensive follow-up beyond 5 years for such patients.Table 3Reported cases of resected remnant pancreatic cancerFirst operationRemnant pancreeatic cancerNoAgeGender (M/F)LocationOperationDifferentiationUICCStageTerm to diagnosisTreatmentDifferentiationUICCStagePrognosisRecurrence formAuthor152FHeadPPPDPapT3N1M0IIB1 year10 monthDP+GRPapNot describedNot described(−)Wada \[[@CR24]\]267FBody/tailDPWellT1N0M0IA7 year4 monthPPPDModeratelyT1N1M0IBAlive(8 month)(−)Eriguchi \[[@CR25]\]358MHeadPPPDPap/wellT2N0M0IB3 yearDPPapT2N0M0IBAlive(6 year3  month)LiverTajima \[[@CR2]\]463MHeadPDWell to moderatelyT3N0M0IIA3 year7 mDPWellnot describedAlive(10 m)(−)Takamatsu \[[@CR22]\]565MHeadPPPDWellT1N0M0IA7 yearDPWellT3N1M0IIBAlive(10 m)(−)Koizumi \[[@CR26]\]667MBodyDPWellT1N0M0IA2 year9 monthPPPDModerate to poorlyT3N1M0IIBAlive(8 month)LiverKoizumi763MHeadPD+PVModeratelyT3N0MXIIA1 yearDP+GR+C(T)RModeratelynot describedAlive(2 year)LNValle \[[@CR21]\]860MBodyDPModeratelyT3N0M0IIA2 year2 monthPPPDPoorlyT2N0M0IBDead(7 month)peritoneumDoi \[[@CR27]\]944MHeadPPPDNot describedT2N1MXIIB3 year 4 monthDPNot describedT2NXM0Alive(22 month)(−)D'Amato \[[@CR28]\]1072FHeadPPPDModeratelyT3N0M0IIA2 year5 monthDP+lateral segmentectomyModeratelynot describedDead(5 month)LiverMiura \[[@CR23]\]1152FHeadPPPDPapT3N1M0IIB1y10 monthDPPapnot describedDead(44 month)Not describedMiura1267MHeadPDWellT2N1M0IIB5y8 monthDPWellnot describedAlive(2 month)(−)Kinoshita \[[@CR29]\]1355FHeadSSPPD+PVAnaplasticT1N0M0IA2 yearDPWellT2N0M0IBAlive(5 year4 8 month)(−)Hashimoto \[[@CR1]\]1469FHeadSSPPDPapT1N0M0IA3 year 2 mmonthDPWellT1N1M0IBAlive(10 month)(−)Hashimoto1580MHeadPPPDModeratelyT3N0M0IIA1 year 9 monthDPModeratelyT3N1M0IIBDead(1 year 6 month)Not describedHashimoto1660MTailDPPapT2N1M0IIB2 year 9 monthTPPapT1N0M0IAAlive(7 year 1 month)(−)Hashimoto1775FTailDPWellT3N1M0IIB3 year 3 monthTPWellT1N0M0IAAlive(1 year 1 month)(−)Hashimoto1876MBodyDPModeratelyT1N0M0IA1 year 11 monthTPModeratelyT3N1M0IIBDead(1 year 1 month)(−)Hashimoto1962FHeadPPPD+PVWellT3N1M0IIB1 year 5 monthchemotherapyNot describednot describedDead(11 month)LiverHashimoto2066MHeadPDModeratelyT3N0M0IIA1y4 mTPModeratelyT3N0M0IIAAlive(61 month)(−)Miyazaki \[[@CR30]\]2168FHeadPD+PVModeratelyT3N1M0IIB3 year 5 monthTPModeratelyT3N0M0IIAAlive(61 month)(−)Miyazaki2262FHeadPD+PVModeratelyT3N1M0IIB2 year 8 monthTPModeratelyT3N1M0IIBDead(15 month)PeritoneumMiyazaki2376FHeadPDWellT3N0M0IIA3 year 5 monthTPModeratelyT3N1M0IIBDead(25 month)Peritoneum,liverMiyazaki2480MBodyDPModeratelyT3N0M0IIA2 yearTPWellT3N0M0IIAAlive(28 monthm)(−)Miyazaki2567MHeadPDModeratelyT2N0M0IB7 year 5 monthTPPoorlyT1N0M0IAAlive(18 month)(−)Miyazaki*PD* pancreaticoduodenectomy, *DP* distal pancreatectomy, *PPPD* pylorus preserving PD, *SSPPD* subtotal stomach preserving pancreaticoduodenectomy, *PV* portal vein resection and reconstruction, *y* year, *m* month, *GR* distal gastrectomy, *C(T)R* toransvers colon resection

The same pathological differentiation of tumors between primary and second operation in our study was recognized in 8 (67 %) of the 12 resected cases, consistent with a previous report indicating 16 (69.6 %) of the 23 described cases as listed in Table [2](#Tab2){ref-type="table"}. Launois et al. \[[@CR31]\] observed 32 % of multifocal carcinomas of the pancreas in a series of 47 total pancreatectomies for patients with PDAC. Likewise, a considerably high incidence of multicentric precancerous foci in the pancreas has been documented in patients with PDAC \[[@CR2]\]. In PDAC, multicentric lesions were found in 16--34 % of cases \[[@CR32]--[@CR35]\], implying that a minute cancerous focus is likely to exist in the remnant pancreas at the time of the initial surgery \[[@CR22]\].

These results suggest that multicentric metachronous pancreatic cancers may develop in the remnant pancreas. Kleff et al. \[[@CR10]\] reported that 7 (3.1 %) of the 227 patients who underwent initial pancreatic resection for pancreatic cancer developed remnant pancreatic cancer, consistent with the incidence of remnant pancreatic cancer in our results. Therefore, multicentric foci of PDAC may develop metachronously not only after a short interval but also after a longer interval as a new primary cancer.

Miyazaki et al. \[[@CR30]\]. reported that repetitive pancreatectomy may be beneficial for the prognosis in selected patients with isolated local recurrence in the remnant pancreas after primary pancreatectomy for pancreatic cancer without increased operative morbidity or mortality. They recognized 11 of 67 patients with isolated local recurrences only in the remnant pancreas who underwent repetitive pancreatectomies. Moreover, at the primary operation, 6 (67 %) of the 9 patients with R0 resection had the same pathological features as in our study.

In this study, we showed that patients with remnant pancreatic cancers who were resected had a better prognosis than those that were unresected. This suggests that remnant pancreatectomy for pancreatic cancer is feasible and may prolong survival. Although early discovery of remnant pancreatic cancer would be difficult, adequate interval follow-up with imaging examinations is important. Further studies are required to elucidate the carcinogenic mechanism in the remnant pancreas.

In conclusion, survivors after curative resection for pancreatic cancer should receive follow-up for the remnant pancreas for an extended period. Aggressive resection of the remnant pancreas should be considered for a more favorable prognosis of patients with PDAC.
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